Skip to content

PolitiKit

Lobbying by Lundbeck Canada Inc.: its registrations, its lobbyists, the bills it has named and every meeting it has reported with federal office holders since November 2021.

← Lobbying

Corporation

Lundbeck Canada Inc.

Meetings this Parliament
0
With MPs
0
Since Nov 2021
2
Active registrations
1

Most recent reported meeting: Sep 6, 2024.

Registrations in effect

In-house (corporation) In effect since Jun 1, 2026

Filed by Jody Engel, President

Lobbyists

  • Jody Engel · President

Institutions they may lobby: Canada Economic Development for Quebec Regions, Canada Foundation for Innovation, Canada Revenue Agency (CRA), Canadian Institutes of Health Research (CIHR), Competition Bureau Canada (COBU), Correctional Service of Canada (CSC), Finance Canada (FIN), Global Affairs Canada (GAC), Health Canada (HC), House of Commons, Immigration, Refugees and Citizenship Canada (IRCC), Indigenous Services Canada (ISC), Innovation, Science and Economic Development Canada (ISED), Justice Canada (JC), National Defence (DND), Patented Medicine Prices Review Board (PMPRB), Prime Minister's Office (PMO), Privy Council Office (PCO), Public Health Agency of Canada (PHAC), Royal Canadian Mounted Police (RCMP), Senate of Canada, Treasury Board Of Canada Secretariat (TBS), Veterans Affairs Canada (VAC)

What they're lobbying on (17)
  • Communicating with government officials about trade between the United States and Canada, including the imposition of potential tariffs (and counter-tariffs) on pharmaceuticals, diagnostics and essential ingredients.
  • Communicating with government officials about the Patent Act, more specifically about the regulation of intellectual property for therapeutic products.
  • Communicating with government officials about the Food and Drugs Act, more specifically about (i) export restrictions, (ii) cross-border trade of biopharmaceuticals, (iii) approval, regulation and life-cycle management of therapeutic products and (iv) data protection.
  • Communicating with government officials about the Scientific Research and Experimental Development ("SR&ED") Tax Incentive Program, more specifically about investments in biopharmaceutical and health technology innovation.
  • Communicating with government officials about regulations, guidelines reviews, references and reporting requirements issued by and/or related to the Patented Medicine Prices Review Board ("PMPRB").
  • Communicating with government officials about regulations related to patented medicines, including the Patented Medicines (Notice of Compliance) Regulations (SOR/93-133) under the Patent Act.
  • Communicating with government officials—including through the pan-Canadian Pharmaceutical Alliance (formerly known as the Pan-Canadian Pricing Alliance)—about drug pricing and reimbursement.
  • Communicating with government officials about the modernization and improvement of Health Canada's "Progressive Licensing Framework".
  • Communicating with government officials about international trade matters, including intellectual property provisions under the Canada-European Union Comprehensive Economic and Trade Agreement (“CETA”) and the Trans-Pacific Partnership (“TPP”).
  • Communicating with government officials about guidance, policies and documents issued by the Office of Patented Medicines and Liaison ("OPML") within the Office of Submissions and Intellectual Property, Therapeutic Products Directorate ("TPD").
  • Communicating with government officials, in general, about programs, reports, reviews and policies issued by or related to Canada's Drug Agency (formerly known as the Canadian Agency for Drugs and Technologies in Health).
  • Communicating with government officials about federal healthcare benefits, including those delivered by members of the Federal Healthcare Partnership ("FHP"), such as the Department of National Defence, the Department of Indigenous Services, the Royal Canadian Mounted Police and the Department of Veterans Affairs.
  • Communicating with government officials, in general, about policies and programs related to improving access for Canadian patients to effective treatments for common mental health, addiction and neuro-degenerative conditions.
  • Communicating with government officials about regulations related to safe and environmentally-responsible disposal of biopharmaceutical compounds, including the Food and Drug Regulations (C.R.C., c. 870) under the Food and Drugs Act.
  • Communicating with government officials about the development of a national pharmacare program with the goal of (i) improving patient well-being and health outcomes and (ii) improving access to effective treatments for patients.
  • Communicating with government officials about data exclusivity, more specifically as it relates to the use of natural health products in biopharmaceutical preparations.
  • Communicating with government officials about initiatives, partnerships research and programs by the Canadian Institutes of Health Research ("CIHR").

Registration 965571-282528-46. Look it up in the official Registry

Reported meetings

Spreadsheet

From the Office of the Commissioner of Lobbying's open data, published November 5, 2026. Reports cover oral, arranged meetings with designated public office holders since November 22, 2021; lobbyists file them by the 15th of the following month. Names of MPs are matched to the current House of Commons, and bills are linked when the lobbyist's own description makes clear which bill it means. Contains information licensed under the Open Data Licence Agreement — Office of the Commissioner of Lobbying. Licence. PolitiKit is independent and is not endorsed by the Commissioner of Lobbying.